From FOMO to FOMU: A Framework for Getting AI Right

Healthcare is a highly regulated industry, and any use of AI within it is dealing with the most sensitive data. In order to ensure you’re not putting you, your company or patients at risk, consider an evaluation framework for any AI tool that considers these three things. The post From FOMO to FOMU: A Framework…

Read More

The wrong people are scared of clinical AI

By CRAIG HAUBEN Ask anyone outside healthcare who resists clinical AI and you’ll get a confident answer. The older doctors. The ones who spent thirty years building expertise and now see a machine coming for it. The story writes itself, which should have been the first clue it was wrong. I’ve spent thirty years in…

Read More

Why 31,000 Kaiser Permanente Workers Are Striking — Again

About 31,000 Kaiser Permanente healthcare workers plan to launch an open-ended strike over staffing shortages, wages and care access issues — potentially affecting dozens of hospitals and hundreds of clinics in California and Hawaii. While Kaiser blames unions for stalled negotiations, workers say the conflict reflects deeper concerns about patient safety, burnout and health systems’…

Read More

Listen: What the Vaccine Schedule Whiplash Means for Your Kids

LISTEN: After a federal judge blocked the Trump administration’s efforts to pare down childhood vaccine recommendations, plenty of questions remain — like how annual vaccines for the flu will get approved. KFF Health News chief Washington correspondent Julie Rovner spoke with WAMU about how the decision is rippling through the public health system. Big swings…

Read More

J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies

Johnson & Johnson’s agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines. The post J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies appeared…

Read More